These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 18662364

  • 1. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
    Barutell C, Camba A, González-Escalada JR, Rodríguez M, Opioid Group of the Spanish Society for the Study of Pain.
    Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
    [Abstract] [Full Text] [Related]

  • 2. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C, Failde I, Micó JA, Neira M, Sánchez-Magro I.
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [Abstract] [Full Text] [Related]

  • 4. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R, Kayser H, Sittl R.
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [Abstract] [Full Text] [Related]

  • 5. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N, Sittl R, Likar R.
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [Abstract] [Full Text] [Related]

  • 6. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M, Ritzdorf I, Brünjes R.
    MMW Fortschr Med; 2008 Sep 18; 150 Suppl 3():142-8. PubMed ID: 19025217
    [Abstract] [Full Text] [Related]

  • 7. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct 18; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

  • 8. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial.
    Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N, Protocol TRP-CAN-1 Study Group.
    J Rheumatol; 2004 Dec 18; 31(12):2454-63. PubMed ID: 15570651
    [Abstract] [Full Text] [Related]

  • 9. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 Dec 18; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M, Berggren AC.
    Clin Ther; 2009 Mar 18; 31(3):503-13. PubMed ID: 19393841
    [Abstract] [Full Text] [Related]

  • 11. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
    Kress HG.
    Eur J Pain; 2009 Mar 18; 13(3):219-30. PubMed ID: 18567516
    [Abstract] [Full Text] [Related]

  • 12. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, Villari P, Casuccio A.
    Clin Ther; 2009 Oct 18; 31(10):2134-8. PubMed ID: 19922884
    [Abstract] [Full Text] [Related]

  • 13. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
    Likar R, Vadlau EM, Breschan C, Kager I, Korak-Leiter M, Ziervogel G.
    Clin J Pain; 2008 Oct 18; 24(6):536-43. PubMed ID: 18574363
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C.
    J Pain Symptom Manage; 2011 Dec 18; 42(6):903-17. PubMed ID: 21945130
    [Abstract] [Full Text] [Related]

  • 15. Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
    Marinangeli F, Ciccozzi A, Aloisio L, Colangeli A, Paladini A, Bajocco C, Coaccioli S, Varrassi G.
    Pain Pract; 2007 Dec 18; 7(4):307-12. PubMed ID: 17986161
    [Abstract] [Full Text] [Related]

  • 16. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study].
    Schutter U, Ritzdorf I, Heckes B.
    MMW Fortschr Med; 2010 Jul 01; 152 Suppl 2():62-9. PubMed ID: 21591321
    [Abstract] [Full Text] [Related]

  • 17. Transdermal buprenorphine in cancer pain and palliative care.
    Sittl R.
    Palliat Med; 2006 Jul 01; 20 Suppl 1():s25-30. PubMed ID: 16764218
    [Abstract] [Full Text] [Related]

  • 18. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
    Apolone G, Corli O, Negri E, Mangano S, Montanari M, Greco MT, Cancer Pain Outcome Research Study Group (CPOR SG) Investigators, Apolone G, Bertetto O, Caraceni A, Corli O, De Conno F, Labianca R, Maltoni M, Nicora Maria F, Torri V, Zucco F.
    Clin J Pain; 2009 Oct 01; 25(8):671-82. PubMed ID: 19920716
    [Abstract] [Full Text] [Related]

  • 19. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study.
    Rodriguez RF, Castillo JM, Del Pilar Castillo M, Nuñez PD, Rodriguez MF, Restrepo JM, Rodriguez JM, Ortiz Y, Angel AM.
    Clin Ther; 2007 Apr 01; 29(4):581-7. PubMed ID: 17617281
    [Abstract] [Full Text] [Related]

  • 20. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies.
    Penza P, Campanella A, Martini A, Melli G, Lombardi R, Camozzi F, Devigili G, Lauria G.
    J Peripher Nerv Syst; 2008 Dec 01; 13(4):283-8. PubMed ID: 19192068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.